Islet microRNAs in health and type-2 diabetes

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Standard

Islet microRNAs in health and type-2 diabetes. / Wendt, Anna; Esguerra, Jonathan LS; Eliasson, Lena.

I: Current Opinion in Pharmacology, Vol. 43, 01.12.2018, s. 46-52.

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Islet microRNAs in health and type-2 diabetes

AU - Wendt, Anna

AU - Esguerra, Jonathan LS

AU - Eliasson, Lena

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Failure of the β-cell to secrete enough insulin is a major contributing factor in the pathogenesis of type-2 diabetes (T2D). MicroRNAs provide an extra layer in the regulation of protein expression, and are thus involved in β-cell compensation during development of the disease. In this review, we discuss how microRNAs can regulate their target protein expression and phenotypic output, present the status of nutritional regulation of microRNA expression, and summarize work on microRNA expression in human islets. In conclusion, current data lend support to microRNAs being essential regulators of insulin secretion. Future work will describe microRNAs in α-cell function, details of the microRNA–mRNA network, and possibilities to use microRNAs as biomarkers and in therapeutic treatment of T2D and complications.

AB - Failure of the β-cell to secrete enough insulin is a major contributing factor in the pathogenesis of type-2 diabetes (T2D). MicroRNAs provide an extra layer in the regulation of protein expression, and are thus involved in β-cell compensation during development of the disease. In this review, we discuss how microRNAs can regulate their target protein expression and phenotypic output, present the status of nutritional regulation of microRNA expression, and summarize work on microRNA expression in human islets. In conclusion, current data lend support to microRNAs being essential regulators of insulin secretion. Future work will describe microRNAs in α-cell function, details of the microRNA–mRNA network, and possibilities to use microRNAs as biomarkers and in therapeutic treatment of T2D and complications.

U2 - 10.1016/j.coph.2018.08.003

DO - 10.1016/j.coph.2018.08.003

M3 - Review article

VL - 43

SP - 46

EP - 52

JO - Current Opinion in Pharmacology

T2 - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4973

ER -